TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05752799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Free Anaesthesia
Description: * 40 mg/kg magnesium sulfate in 100 ml N/S infusion~* 0.4 mcg/kg dexmedetomidine, max total dose 50mcg in 50 ml N/S infusion~* 0.3 mg/kg ketamine in 10 ml volume~* 0.2 ml/kg of the Multimix regimen in 100 ml N/S infusion as a bolus (The Multimix regimen consists of 50mcg dexmedetomidine, 500 mg lidocaine and 50mg ketamine).~* 0.2 ml/kg/h of the Multimix regimen in 100 ml N/S infusion as a continuous infusion. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value \> 25 or elevation of Heart Rate and/or Blood Pressure \>20%.~Placebo infusions of normal saline will be prepared to enable blinding.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid based anesthesia
Description: * 2 mcg/kg fentanyl in 10 ml volume~* 0.2 mL/kg/h remifentanil infusion~* 0.1 mg/kg morphine. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value \> 25 or elevation of Heart Rate and/or Blood Pressure \>20%.~Placebo infusions of normal saline will be prepared to enable blinding.
Study: NCT05347758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535
Description: Drug: HRS-7535

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo
Study: NCT06361901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenicog;language rehabilitation program
Description: This program is an AI-based computerized cognitive and language training program.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional language rehabilitation
Description: Conventional language rahabilitation therapy will apply for all participants with speech impairement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional language rehabilitation
Description: Conventional language rahabilitation therapy will apply for all participants with speech impairement
Study: NCT05776953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: IV Ketorolac for pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: IV Ketorolac for pain
Study: NCT05687955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip Exercise Program
Description: The exercise intervention is being implemented 3 times per week. Two sessions can be completed at home by the participant, and one session per week will be attended by a physiotherapist that will monitor exercise technique and progress the exercise program for each participant. The exercise protocol has been specifically designed to focus on hip rehabilitation appropriate for circus performance. The exercise program will involve hip strength exercises in the sagittal, coronal and transverse planes using weights and elastic bands (Theraband). It will also include trunk strength and postural correction exercises to address swayback posture which is a common clinical presentation in those with hip dysplasia.
Study: NCT05906082

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care control using standard national resources
Description: This is the standard care with national resources from smokefree.gov.
Study: NCT06530251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: Following a predefined dose and date.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: Following a predefined dose and date.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: Following a predefined dose and date.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: Following a predefined dose and date.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Following a predefined dose and date.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK127
Description: Following a predefined dose and date.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK130
Description: Following a predefined dose and date.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab Injection
Description: Following the local label direction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab biosimilar
Description: Following the local label direction.
Study: NCT06244550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganwei
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganwei
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching capsules
Study: NCT05865496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611
Description: 611 subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611
Description: 611 subcutaneous (SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous (SC) injection.
Study: NCT05882110

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cultured autologous epidermal cell membrane
Description: The cultured autologous epidermal cell membrane is made from the patient's autologous epidermal cells by in vitro rapid expansion and culture technology, which has good biocompatibility, non-toxic, non-teratogenic, can reduce the skin area cut by traditional autologous skin grafting methods, and has high proliferative activity to promote wound repair and regeneration.
Study: NCT05531279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected; PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected; RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected; PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected; RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected; PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected; RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.
Study: NCT04715516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: alcohol brief intervention
Description: Nested within the lifestyle health promotion provided in both conditions, participants randomised to the experimental condition will receive an alcohol brief intervention. The strong evidence-base for alcohol brief intervention, amplified by Co-Investigators' Smith and Bragge's (BehaviourWorks) approaches to applied behaviour change, has provided the framework for the development of the alcohol brief intervention used in this study. This intervention comprises personalised feedback on alcohol consumption levels, comparison to gender/age drinking norms, and information and behaviour-change content regarding alcohol consumption (i.e. negative-framed messaging around alcohol risks and harms, positive-framed messaging on the health benefits of reducing alcohol intake, alcohol harm reduction strategies).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle health promotion
Description: Lifestyle health promotion specific to physical activity and maintaining a healthy weight, developed to be relevant to women attending breast screening services, will be provided.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: lifestyle health promotion
Description: Lifestyle health promotion specific to physical activity and maintaining a healthy weight, developed to be relevant to women attending breast screening services, will be provided.
Study: NCT05673239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocarnitine Injection
Description: The patients in the test group were injected with 1-2g (10-20mg/kg) levocarnitine on each dialysis day
Study: NCT05613790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active High-Definition Transcranial Direct Current Stimulation (HD-tDCS)
Description: Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham High-Definition Transcranial Direct Current Stimulation (HD-tDCS)
Description: Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.
Study: NCT05040555

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: R-CDOP
Description: Rituximab 375mg/m2, D0; Cyclophosphamide 750mg/ m2, D1; Doxorubicin hydrochloride liposome 30-35mg/ m2, D1; Vindesine 3mg/ m2, D1; Prednisone 60mg/ m2, D1\~5.
Study: NCT04700501

Intervention type: OTHER
Group type: OTHER
Intervention: Enjoy Your Bump - CBT life skills learning programme
Description: Antenatal use of an online Cognitive Behavioural Therapy life skills learning programme to improve maternal feelings of anxiety and low mood.
Study: NCT05773560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality rehabilitation
Description: All patients will receive VR-assisted rehabilitation. The VR-assisted rehabilitation is proceed with SyncVR® (Padualaan, Netherlands ) equipment, which is composed of a head set (PICO NEO 3) and one dashboard (TABLET), enabling the patients to receive stepwise rehabilitation program with 360° videos activities (SyncVR Medical Platform). The VR-assisted rehabilitation will be performed two times per day, 30 minutes per training. The first training will start on the second post-operative day.
Study: NCT05403164

Intervention type: PROCEDURE
Intervention: Modified Widman flap
Description: 1. Administration of anaesthesia~2. First incision (reversed bevel incision), scalpel is placed at 45 degree, 2mm apical to gingival margin in coronal-apical direction until touching the bone and moved continuously around the teeth without any vertical releasing incisions~3. Partial mobilization of the mucoperiosteal flap (full thickness flaps both facially and orally) within the attached gingiva to the alveolar crest~4. Second incision (sulcular incision)~5. Third incision (horizontal incision), also interdentally to remove the delineated tissue and all granulation tissue which is used later for analysis.~6. Root surface debridement~7. Flap adaptation, complete coverage interdentally and suturing.

Intervention type: PROCEDURE
Intervention: Gingivectomy
Description: 1. Administration of anaesthesia~2. Marking the base of the sulcus with pocket marker tweezer.~3. First incision (gingivectomy incision), scalpel blade placed 1mm apical to the bleeding points and the incision should be beveled 45 degrees coronally.~4. Second incision (interdental) to free the tissue which is used for analysis later.~5. Debriding the area and applying periodontal pack.
Study: NCT04863625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a peer-led educational intervention based on theory of planned behavior on substance use intentions and behaviors
Description: The intervention will be a peer led education process on substance use (smoking, drinking and chewing) prevention based on the Theory of Planned Behavior (TPB).The intervention aims to encourage anti-substance attitudes and beliefs; foster perceptions of normative support for anti-substance behavior; increase perceptions of control/self-efficacy to resist substance use, increase knowledge and risk perceptions on substance and decrease in intention to use substance and actual substance use behaviors. Six education sessions will be delivered, with one session occurring each week. Each session will be lasted 40-55 minutes. The intervention will be conducted in 30 groups of selected students from grade 9-12, a pair of peer educators will educate a 30 sized group weekly (30 students /group)/ classrooms at pre-assigned time during class periods. The six sessions will be guided by four student training modules.
Study: NCT05545891

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A drug that contains no medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Atypical antipsychotic medication
Study: NCT05668169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family-centered support program for caregivers of stroke survivors
Description: Once participants joined the family-centered support group, participants received 90-minute interventions, including an introduction to stroke and rehabilitation education, problem-solving skills training, and long-term care information. Investigators also invited participants to join the instant messaging application-based 24-h peer-support group for caregivers. On the second and fourth days after receiving the interventions, the researcher visited the participants to review and practice the content provided on the first day; each session was 30 to 40 minutes long. The researcher contacted the participants one week after participants joined the study to discuss their care difficulties or experiences and did so three times biweekly thereafter via the instant messaging application.
Study: NCT05151068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: traditional nursing method
Description: ①Preoperative education, informing patients of the importance of the tube and the adverse effects of unauthorised extubation after the operation on the recovery of the disease. ②Pipe care: The nose wing is fixed with modified human elastic tape, and the same side cheek bridge is fixed to keep the duct unobstructed and pour gastric juice in time. ③Oral care: routinely brush teeth and gargle with mouthwash daily. ④Skin care: Observe the condition of the nose, cheek skin and oral and nasal mucosa. Replace the tape as needed, and clean the skin before fixing. ⑤ Pain care: assess the degree of pain, follow the doctor's prescription for medication, and observe the efficacy of medication. ⑥Psychological care: pay attention to the emotional changes of patients and provide psychological support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Precise acupoint application combined with ear acupoint embedding nursing program
Description: On the basis of conventional nursing, the experimental group adopted a precision nursing program of acupoint application combined with ear acupoint embedding.
Study: NCT06463444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC + Tislelizumab +lenvatinib
Description: All patients were treated with HAIC combined with tislelizumab and lenvatinib.~1. HAIC was adopted of the FOFOLX 6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days.~2. Lenvatinib was started before HAIC treatment, discontinued during HAIC treatment, Oral 8 mg or 12mg once a day depending body weight.~3. First treatment with Tislelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later.
Study: NCT05807113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atopi intensive care BNO 3731
Description: Crem twice daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Benchmark product
Description: Crem twice daily
Study: NCT05980208

Intervention type: DRUG
Intervention: Inetetamab
Description: Inetetamab-based treatment for first-line treatment of HER2-positive MBC
Study: NCT05987306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss plus self-compassion
Description: A novel weight loss approach combining a standard weight loss based on the Diabetes Prevention Program and internalized weight bias intervention with self-compassion exercises.
Study: NCT04999982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening
Description: Parent-report screening for remediable, unmet social needs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resource Packet
Description: Provision of packet of resource sheets (Family Resource Booklet) detailing local community-based resources to address these needs, with needs that respond to family's requests highlighted.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resource Navigation
Description: Navigation to resources, care coordination, and parent support provided by a trained bachelors-level interventionist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: Screening for social needs annually at well-child visits as recommended by the AAP followed by provision of information as needed by the family.
Study: NCT05093504

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Sham comparator in similar position to the investigational device, but NOT integrated into the cardiopulmonary bypass (CPB) circuit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DrugSorb-ATR system
Description: Sorbent hemoperfusion system integrated into the cardiopulmonary bypass (CPB) circuit
Study: NCT06086210

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy
Description: Low-level laser therapy was applied to each area for 1 minute, with a wavelength of 808 nm and a dose of 2j/cm2 for a total of 5 minutes,10j/cm2 in continuous mode. A total of 15 sessions were applied 5 days a week for 3 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham therapy was applied to each area for 1 minute, with a wavelength of 0 nm and a dose of 0j/cm2 for a total of 5 minutes, 0j/cm2. A total of 15 sessions were applied 5 days a week for 3 weeks.
Study: NCT05704374

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: sympathetic stimulation maneuver (mental arithmetic test, cold pressure test)
Description: Mental arithmetic calculation and cold pressure increase sympathetic tone. For the mental arithmetic task, the subject is asked to mentally subtract a two-digit number from a four-digit number and respond within 5 seconds. This arithmetic calculation is repeated for different numbers. This test is continued for three minutes. For the cold pressure test, subjects are asked to immerse their right hand in 2-4 degrees cold water up to the elbow and hold it in the water for three minutes. The mental arithmetic task and cold stress test will be applied simultaneously.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: sympathetic stimulation maneuver (mental arithmetic test, cold pressure test)
Description: Mental arithmetic calculation and cold pressure increase sympathetic tone. For the mental arithmetic task, the subject is asked to mentally subtract a two-digit number from a four-digit number and respond within 5 seconds. This arithmetic calculation is repeated for different numbers. This test is continued for three minutes. For the cold pressure test, subjects are asked to immerse their right hand in 2-4 degrees cold water up to the elbow and hold it in the water for three minutes. The mental arithmetic task and cold stress test will be applied simultaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: In the second phase of the experiment, 150 mg (single dose) of pregabalin will be given to FMS patients to reduce sympathetic activity and evaluate its effect on T- and H-reflexes.
Study: NCT06271772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate Ophthalmic
Description: Difluprednate 0.05% is a corticosteroid used to reduce inflammation in the eye. Participants will receive one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of steroid therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate Ophthalmic
Description: Difluprednate 0.05% is a corticosteroid used to reduce inflammation in the eye. Participants will receive one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of steroid therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rose Bengal
Description: Study participants receive RB-PDT within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.1% RB in 0.9% sodium chloride) which will be applied in 3-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected within 24 hours after the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Ophthalmic
Description: Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Ophthalmic
Description: Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.
Study: NCT05323240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PM exposure
Description: To determine whether 3-day consecutive exposures to levels of fine particulate matter (PM2.5) that are close to the current 24-hr national standard will cause changes in inflammatory and cardiopulmonary endpoints.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filtered air exposure
Description: To determine whether 3-day consecutive exposures to filtered air will cause changes in inflammatory and cardiopulmonary endpoints.
Study: NCT05669131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery training
Description: Participants imagine themselves through their own eyes performing submaximal elbow flexion contractions.
Study: NCT05284864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stoma closure
Description: Stoma closure after rectal surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stoma closure
Description: Stoma closure after rectal surgery
Study: NCT04826965

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Vac is applied
Description: A wound vac or wound vac with cleanse choice dressing, track pad duo, and saline irrigation is applied.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Vac is applied
Description: A wound vac or wound vac with cleanse choice dressing, track pad duo, and saline irrigation is applied.